COMMUNIQUÉS West-GlobeNewswire

REGISTRATION OF CAPITAL INCREASE OF DKK 92,076 AA SHARES AND DKK 920,760 B SHARES BY THE ISSUE OF NEW SHARES COMPLETED

11/12/2017 - 10:51

Copenhagen, 2017-12-11 10:51 CET (GLOBE NEWSWIRE) -- This release does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States, [...]

Nexstim Plc has entered into an agreement on a financing arrangement that is conditional on the approval of the Annual General Meeting

11/12/2017 - 08:01

Company announcement, Helsinki, 11 December 2017, at 9.00 AM Nexstim Plc has entered into an agreement on a financing arrangement that is conditional on the approval of the Annual General Meeting Nexstim Plc (NXTMH:HEX [...]

Galapagos to enter NASDAQ Biotech Index

11/12/2017 - 07:31

Mechelen, Belgium; 11 December 2017; 7.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) announces that it will be included in NASDAQ Biotech Index on NASDAQ, effective 18 December 2017. The NASDAQ Biotech Index (NBI [...]

argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting

11/12/2017 - 07:06

Workshop to be held on Monday, December 11 th at 12:00 pm EST December 11, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company developing a deep [...]

Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews

11/12/2017 - 07:01

Oslo, Norway, 11 December 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that clinical trials investigating ONCOS-102 in the [...]

argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

11/12/2017 - 07:01

Favorable tolerability profile consistent with Phase 1 data ARGX-113 treatment resulted in a strong clinical improvement over placebo during the entire duration of the study 75% of ARGX-113 treated patients had a [...]

Agios Presents Updated Data from DRIVE PK Study Demonstrating AG-348 is Well-Tolerated and Results in Clinically Relevant, Rapid and Sustained Hemoglobin Increases in Patients with Pyruvate Kinase Deficiency

11/12/2017 - 00:00

– Safety and Efficacy Profile Consistent with Previously Reported Data – – Hemoglobin Increases >1.0 g/dL in 26 of 52 Patients Overall; Responses Remain Durable with Completion of Six Month Core Treatment Period – – [...]

ZIOPHARM Announces Presentation of Data from T-Cell Therapy Programs at ASH Annual Meeting

10/12/2017 - 23:00

– Clinical data show continued survival benefit, tumor response, and multi-year persistence of Sleeping Beauty -modified CD19-specific CAR + T cells – – Point-of-care CD19-specific CAR + T cells co-expressing mbIL15 [...]

Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer

10/12/2017 - 16:39

At six months, 30% of patients treated with Kymriah were in complete response, with a 74% relapse-free rate after onset of response; median duration of response was not reached Grade 3/4 neurologic events occurred in 12 [...]

Epizyme Presents New Biomarker Data on Tazemetostat at the American Society of Hematology Annual Meeting

10/12/2017 - 16:00

CAMBRIDGE, Mass., Dec. 10, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ: EPZM ), a clinical-stage biopharmaceutical company developing novel epigenetic therapies, today announced that two presentations reinforcing its [...]

Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients

10/12/2017 - 15:00

39% ORR for G100+pembrolizumab is greater than either agent alone; reaches 57% ORR in the TLR4 high patient population receiving G100+pembrolizumab (potential predictive biomarker) Responses occur in both recurrent/ [...]

Kura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia

10/12/2017 - 15:00

– Primary objective met with three objective responses in nine patients with RAS wild-type tumor status (33%), two additional RAS wild-type patients pending best response evaluation – – All nine evaluable patients with [...]

On Cancellation of the Webinar Scheduled for December 12

10/12/2017 - 13:45

Olaine, 2017-12-10 13:45 CET (GLOBE NEWSWIRE) -- AS Olainfarm hereby informs, that 3rd quarter webinar scheduled for 4:00 p.m. Latvian time on December 12, 2017 is cancelled. Company will publish a separate announcement [...]

CRISPR Therapeutics Announces Oral Presentation of New Data on CTX001, a CRISPR Gene-Edited Therapy for β-Thalassemia and Sickle Cell Disease, at the ASH Annual Meeting

10/12/2017 - 13:45

ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 10, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP ) today announced the presentation of new data on CTX001, an investigational CRISPR gene-edited therapy for [...]

Valerijs Maligins, Chairman of the Board of AS Olainfarm Has Passed Away

10/12/2017 - 13:33

Olaine, 2017-12-10 13:33 CET (GLOBE NEWSWIRE) -- Valerijs Maligins became Chairman of Olainfarm’s Board after the privatization of the company in 1997. Under his management, the company became one of the most valuable [...]

Bellicum Announces Data Presentation Demonstrating Improved Immune Recovery Following Haploidentical Stem Cell Transplant with BPX-501 in Children with Blood Cancers and Nonmalignant Diseases

09/12/2017 - 20:00

ATLANTA, Dec. 09, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM ), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today [...]

BeiGene Presents Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) in Non-Hodgkin’s Lymphoma at the 59th American Society of Hematology Annual Meeting

09/12/2017 - 18:15

CAMBRIDGE, Mass. and BEIJING, China, Dec. 09, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly [...]

GBT Announces New Phase 2a Data at ASH for Voxelotor in Adolescents with Sickle Cell Disease (SCD)

09/12/2017 - 16:00

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT ) today announced new results from its ongoing Phase 2a HOPE-KIDS 1 Study of once-daily oral therapy, [...]

Catalyst Biosciences Announces Interim Phase 1/2 CB 2679d/ISU304 Results at the American Society of Hematology Conference

09/12/2017 - 15:30

Subcutaneous (SQ) delivery significantly increases half-life of CB 2679d to 98.7 hours Data supports potential normalization of FIX activity with daily or less-frequent SQ dosing SOUTH SAN FRANCISCO, Calif., Dec. 09, [...]